Evaluate Vantage Homepage
The group’s Covid-19 vaccine is on course for UK approval – but the UK doesn’t want it.
Astrazeneca’s Himalaya study is a surprising hit in first-line liver cancer, but competition is already present.
But a potentially more interesting advisory committee, for Merck and Ridgeback’s molnupiravir, awaits.
And when the long-awaited trial does finally report it will have to be a smash hit.
The young biotech is well placed to deliver its first pivotal win, but investor focus might lie elsewhere.
Chemocentryx and Avadel will also see important FDA regulatory action this month, while Omeros gets another delay.
Data are due in the fourth quarter for Aldeyra, Aeglea and Radius, among other small developers.
Deals this week with a UK consortium and Oxford Biomedica see the group bet on lentiviral vectors.
The group hopes phase 2 data will back approval for its amyotrophic lateral sclerosis project AMX0035 after all.